Additive inhibitory effects of simvastatin and enzalutamide on androgen-sensitive LNCaP and VCaP prostate cancer...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Prostate cancer growth is driven by androgen signaling.
• Androgen deprivation therapy (ADT) is a standard treatment.
• Statins are cholesterol-lowering drugs with potential anti-cancer effects.

Purpose of the Study:

• To investigate the combined effects of simvastatin and enzalutamide on prostate cancer cell growth and androgen signaling.
• To explore the mechanisms underlying statin-induced growth inhibition.
• To assess the potential of statins in combination with ADT.

Main Methods:

• In vitro evaluation of simvastatin and enzalutamide on LNCaP and VCaP prostate cancer cells.
• Analysis of androgen receptor (AR) and prostate-specific antigen (PSA) protein expression.
• Assessment of cell growth inhibition and autophagy induction.

Main Results:

• Simvastatin alone inhibited androgen-induced growth in both cell lines.
• Simvastatin reduced AR and PSA expression in LNCaP cells, but not VCaP cells, suggesting AR-independent effects.
• Combination therapy showed additive growth inhibition and induced autophagy in LNCaP cells.

Conclusions:

• Simvastatin and enzalutamide exhibit additive effects on prostate cancer cell growth inhibition.
• Statin-induced growth inhibition may involve mechanisms beyond AR transcriptional activity.
• Statins hold promise for enhancing androgen deprivation therapy in prostate cancer treatment.